

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1681)**

## **VOLUNTARY ANNOUNCEMENT BUSINESS UPDATES**

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the updates on the development of the business of the Group.

Reference is made to the voluntary announcements of the Company dated 17 August 2021, 20 March 2022 and 20 June 2022 regarding (i) the establishment of a wholly-owned subsidiary, Consun Pharmaceutical (Horgos) Co., Ltd.\* (康臣藥業(霍爾果斯)有限公司) (“**Consun Pharmaceutical (Horgos)**”), in Horgos, Xinjiang, by Consun Pharmaceutical (Inner Mongolia) Co., Ltd.\* (康臣藥業(內蒙古)有限責任公司), a wholly-owned subsidiary of the Company; (ii) the press conference held in Horgos Economic Development Zone in Xinjiang announcing, among other things, an extension of the preferential enterprise income tax policies to 2030; and (iii) on 18 June 2022, the trial production ceremony held by Consun Pharmaceutical (Horgos) in Plant No. 8, Area A05, Horgos Comprehensive Bonded Zone, Yili Kazakh Autonomous Prefecture, Xinjiang Uygur Autonomous Region (“**Xinjiang Plant**”), marking the first fully automatic production line of Chinese medicine granules officially completed and put into trial production, with an annual production capacity of approximately 100,000 pieces (boxes), respectively.

On 25 October 2023, Consun Pharmaceutical (Horgos) held a construction commencement ceremony for the second fully automatic production line of Chinese medicine granules in Xinjiang Plant. The construction period of the new production line is expected to be about one year, with a designed annual production capacity of approximately 150,000 pieces (boxes). After the production line is completed and put into operation, the total annual production capacity of Consun Pharmaceutical (Horgos) is expected to reach approximately 250,000 pieces (boxes). The Group believes that the construction of the second fully automatic production line of Consun Pharmaceutical (Horgos) can appropriately cope with the growing market demand for the Group’s products.

By order of the Board of  
**Consun Pharmaceutical Group Limited**  
**An Meng**  
*Chairman*

Hong Kong, 25 October 2023

*As at the date of this announcement, the Board comprises Mr. An Meng, Ms. Li Qian, Professor Zhu Quan and Mr. Xu Hanxing as executive directors; Ms. Zhang Lihua as a non-executive director; and Mr. Su Yuanfu, Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive directors.*

\* *For identification purpose only*